AN2 Therapeutics (ANTX) Change in Acquisitions & Divestments (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Change in Acquisitions & Divestments for 6 consecutive years, with $11.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 65.1% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $54.0 million (down 49.33% YoY), while the FY2025 annual figure was $74.5 million, down 26.49% from the prior year.
• Change in Acquisitions & Divestments slipped to $11.0 million in Q1 2026 per ANTX's latest filing, from $15.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $31.5 million in Q1 2025 and bottomed at $10.0 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $20.5 million across 5 years, with a median of $20.2 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments surged 66.28% — and 2026, when it tumbled 65.1%.
• AN2 Therapeutics' Change in Acquisitions & Divestments stood at $23.5 million in 2022, then retreated by 13.83% to $20.2 million in 2023, then fell by 13.58% to $17.5 million in 2024, then fell by 11.43% to $15.5 million in 2025, then slipped by 29.08% to $11.0 million in 2026.
• Business Quant data shows ANTX's Change in Acquisitions & Divestments at $11.0 million in Q1 2026, $15.5 million in Q4 2025, and $10.0 million in Q3 2025.